How Does Succinylcholine Cause Hyperkalemia?

Succinylcholine causes hyperkalemia by forcing potassium out of muscle cells when it activates acetylcholine receptors on the muscle membrane. In a healthy person, this potassium shift is small and clinically harmless. But in patients with certain conditions, the number of these receptors multiplies dramatically across the entire muscle surface, and the resulting flood of potassium into the bloodstream can be large enough to stop the heart. Understanding which patients are vulnerable and why is one of the most important safety considerations in anesthesia and emergency medicine.

What Happens at the Muscle Membrane

Under normal conditions, acetylcholine receptors sit in a tight cluster at the neuromuscular junction, which is the narrow point where a nerve meets a muscle fiber. When succinylcholine binds to these receptors, it mimics acetylcholine and causes the ion channel in each receptor to open. That opening allows sodium to rush into the cell and potassium to flow out. In a healthy adult with receptors confined to the junction, this potassium leak raises blood levels by a modest amount, roughly half a milliequivalent per liter. The body handles that easily. The kidneys and cellular buffering systems bring potassium back to normal within minutes, and no harm is done.

The trouble begins when receptors are no longer confined to the junction. In various disease states, the muscle membrane sprouts acetylcholine receptors far beyond the normal cluster, spreading them across its entire surface. When succinylcholine then depolarizes millions of these extra receptors simultaneously, the potassium efflux is no longer a trickle. It becomes a surge large enough to raise blood potassium to levels that disrupt cardiac rhythm.

Why Receptor Upregulation Changes Everything

The process that scatters receptors across the muscle membrane is called upregulation. In a healthy muscle that receives regular nerve signals, the body suppresses receptor production everywhere except the junction. But when the nerve signal is lost or the muscle goes unused, the cell reverts to a more primitive state. It begins manufacturing receptors along the entire membrane, including immature receptor subtypes that stay open longer when activated and allow even more potassium through per channel.

This upregulation has been documented in a wide range of conditions: upper or lower motor neuron injuries, chemical denervation from prolonged use of muscle relaxants, immobilization, direct muscle trauma, burn injury, muscle tumors, and muscle inflammation, among others.¹ The common thread is that the muscle has lost its normal nerve input or its normal use. In all of these scenarios, the depolarization of receptors spread across the full membrane surface by succinylcholine leads to a potassium release far beyond what the junction alone would produce.

The development of these extra receptors is not instantaneous. Research on disuse atrophy in animal models suggests that the upregulation is progressive, depending on the gradual spread of new receptors beyond the endplate region over days to weeks.² This time course matters clinically. In many high-risk conditions, there is a window after the initial injury during which succinylcholine could still be used with relative safety. After that window closes, the danger increases substantially and can persist for months or even longer.

Burns, Spinal Cord Injuries, and Prolonged Immobilization

Major burn injuries are one of the best-recognized risk factors. In 1969, experiments clearly demonstrated that succinylcholine could cause dangerous hyperkalemia in burn patients, and the association has been a textbook warning ever since.³ The receptor proliferation in burn patients is thought to begin within days of the injury and can persist long after the skin has healed, because the underlying muscle damage and inflammation keep the receptors in their upregulated state.

Spinal cord injuries carry a similar risk. Patients with paraplegia or quadriplegia lose nerve input to large muscle groups, triggering widespread receptor upregulation below the level of injury. Case reports have documented rapid-onset hyperkalemia leading to cardiac arrest in patients with thoracolumbar spinal cord injuries who received succinylcholine during anesthesia induction.⁴ The risk period in spinal cord injury is generally considered to begin a few days after injury and to last at least six months, though some guidelines extend the caution indefinitely.

Prolonged immobilization in intensive care units poses its own version of the same problem. Patients who have been chemically paralyzed with nondepolarizing muscle relaxants for extended periods develop receptor changes similar to those seen with denervation. When succinylcholine is then given, the widespread receptors produce a dangerous potassium release. Case reports have emphasized that succinylcholine should be used with extreme caution in patients who have been pharmacologically paralyzed in the ICU for more than a few days.⁵

Severe Infections as a Less Obvious Trigger

While burns and paralysis are widely taught as risk factors, severe infections represent a category that is easier to overlook. A study of patients undergoing repeat operations for severe intra-abdominal infections found striking results. Among nine patients, four showed serum potassium increases ranging from 2.5 to 3.1 mmol per liter above baseline within three to six minutes of receiving succinylcholine. The other five showed no change. The distinguishing factor was the duration of illness: the four who developed hyperkalemia had been febrile with signs of infection for at least two weeks, while the five who did not had been sick for nine days or fewer.⁶

A separate study confirmed this pattern, finding that patients with intra-abdominal infections lasting more than seven days showed significant potassium elevation after succinylcholine, with peak levels at five and ten minutes after administration.⁷ The mechanism is likely a combination of inflammation-driven receptor changes and the immobilization that comes with prolonged critical illness. Patients who have been bedridden and septic for a week or more may have enough receptor upregulation to make succinylcholine hazardous, even though they have no obvious neuromuscular disease.

This finding complicates clinical decision-making. In an emergency, such as a patient with a perforated bowel who needs rapid intubation, succinylcholine’s speed is extremely valuable. But if that patient has already been critically ill and immobile for two weeks, the drug that would be first-choice in a healthier person becomes a potential trigger for cardiac arrest. The duration of illness, not just the presence of infection, seems to be what tips the balance.

Children With Undiagnosed Muscle Disease

Some of the most tragic cases of succinylcholine-induced hyperkalemia have involved children who appeared healthy but were harboring an undiagnosed muscular dystrophy. Because conditions like Duchenne and Becker muscular dystrophy can be clinically subtle in very young children, the first sign of the disease may be a catastrophic reaction to succinylcholine during what was expected to be a routine anesthetic.

In one reported case, a three-year-old boy with undiagnosed Duchenne muscular dystrophy suffered cardiac arrest after a single dose of succinylcholine during a halothane anesthetic. The arrest was accompanied by muscle rigidity, an absence of the normal muscle twitching that succinylcholine usually causes, massive potassium elevation, and breakdown products of muscle tissue in the urine.⁸ In other reported cases, two pediatric patients developed life-threatening arrhythmias after routine anesthesia induction with succinylcholine. Subsequent testing revealed Duchenne muscular dystrophy in one and Becker muscular dystrophy in the other. Neither condition had been previously suspected. The mechanism in these cases is thought to be hyperkalemia from muscle cell breakdown, triggered by a combination of the drug’s depolarizing action and the inherent fragility of dystrophin-deficient muscle.⁹

These cases were a major factor behind the decision by regulatory agencies in many countries to restrict or warn against the routine use of succinylcholine in children. The reasoning is straightforward: muscular dystrophy affects roughly one in several thousand boys, it may not be diagnosed until age four or five, and the consequences of giving succinylcholine to an affected child can be fatal. For elective pediatric procedures, nondepolarizing agents are now preferred. Succinylcholine is still available for emergencies where no alternative provides equally rapid paralysis, but the risk-benefit calculation is different in children than in adults precisely because of the possibility of hidden myopathy.

Sepsis and Critical Illness in Pediatric Patients

The risk in children extends beyond undiagnosed myopathy. A case report documented hyperkalemia and cardiac arrest following succinylcholine in a 16-year-old with leukemia and sepsis. The patient had been immobilized and critically ill, creating the same conditions for receptor upregulation seen in adults.¹⁰ The conclusion from such reports is that nondepolarizing agents should be the default choice for any child who is septic and immobilized, regardless of whether they have a known neuromuscular condition.

What makes critical illness in children particularly treacherous is that multiple risk factors often overlap. A child in the ICU may be immobilized, infected, receiving medications that affect the neuromuscular junction, and possibly harboring an undiagnosed genetic condition, all at once. Each factor alone might produce a modest degree of receptor upregulation; together, they create conditions for a catastrophic potassium surge.

How Much Potassium Is Too Much

To understand why this matters so urgently, it helps to know how sensitive the heart is to potassium levels. Normal blood potassium is roughly 3.5 to 5.0 milliequivalents per liter. At levels above about 6.0, the electrical conduction system of the heart starts to malfunction. Above 7.0 or so, the risk of fatal arrhythmias climbs sharply. In the infection study referenced earlier, some patients saw potassium jumps of 2.5 to 3.1 mmol per liter above baseline within minutes.⁶ If a patient’s baseline is already near the high end of normal, as it often is in critically ill or renal failure patients, that kind of jump pushes potassium to immediately life-threatening levels.

The speed of the rise is part of what makes it dangerous. Most causes of hyperkalemia develop gradually, giving the heart time to partially adapt. Succinylcholine-induced hyperkalemia peaks within minutes, often faster than the body’s compensatory mechanisms can respond. In emergency settings, this rapid onset may manifest as widening of the QRS complex on a cardiac monitor, a sign that the heart’s electrical conduction is slowing dangerously.¹¹ If potassium continues to rise or if treatment is delayed, the progression can move to ventricular fibrillation or asystole.

The List of Conditions That Should Raise a Red Flag

Given the range of conditions implicated, clinicians need a practical mental checklist. The following conditions are associated with receptor proliferation and heightened risk of succinylcholine-induced hyperkalemia:¹²

Upper motor neuron injuries: stroke, spinal cord injury above the level of the lesion, or other brain and spinal cord damage that disrupts signals to muscles.
Lower motor neuron injuries: damage to the peripheral nerves themselves, as in certain neuropathies or spinal cord injuries at the level of the motor neurons.
Major burns: particularly when more than a small percentage of body surface area is affected, and for months after the initial injury.
Prolonged immobilization: whether from coma, chemical paralysis in the ICU, body casting, or simply being bedridden for extended periods.
Muscular dystrophy: both diagnosed and, critically, undiagnosed forms in children.
Prolonged critical illness: especially with sepsis and immobility lasting more than a week.
Direct muscle trauma: crush injuries or extensive surgical dissection of muscle.
Muscle tumors or inflammation: conditions that disrupt the normal architecture and innervation of muscle tissue.

Patients with pre-existing hyperkalemia from kidney failure or other metabolic causes are also at elevated risk, not because of receptor changes, but because their baseline potassium is already high. Even the normal half-milliequivalent bump from succinylcholine can push them over the edge.

Why Succinylcholine Is Still Used Despite the Risk

Given all these dangers, a reasonable question is why anyone still uses succinylcholine at all. The answer is speed. Succinylcholine produces complete muscle paralysis faster than any alternative, typically within about 60 seconds. In emergency situations where a patient needs to be intubated immediately, such as a full-stomach patient at risk of aspirating vomit into the lungs, that speed advantage can be the difference between securing the airway and a fatal aspiration. No nondepolarizing agent matches it for onset time, though rocuronium at high doses comes close and has largely replaced succinylcholine in many emergency departments and operating rooms.

The drug also wears off quickly. Its action lasts only a few minutes because it is rapidly broken down by an enzyme in the blood. This short duration is a safety feature in situations where intubation fails: the patient regains the ability to breathe on their own within minutes, whereas a longer-acting paralytic would leave them unable to breathe and potentially impossible to ventilate. For patients without risk factors for hyperkalemia, succinylcholine remains a useful and reasonably safe tool.

The clinical calculation, then, is about matching the drug to the patient. In a previously healthy adult presenting to the emergency department with no history of neuromuscular disease, burns, immobilization, or prolonged illness, succinylcholine is a reasonable choice for rapid-sequence intubation. In a patient with any of the risk factors discussed above, alternative agents should be used. The problem, as the pediatric cases illustrate, is that not all risk factors are visible before the drug is given.

How the Danger Was Recognized

Succinylcholine was introduced into clinical practice in the early 1950s and quickly became one of the most widely used drugs in anesthesia. The hyperkalemia risk was not immediately apparent. Animal studies first reported a transient rise in plasma potassium in 1960, and it was not until 1969 that experiments clearly demonstrated the problem in burn patients.³ Through the 1970s, 1980s, and 1990s, additional high-risk populations were identified one by one, often through case reports of cardiac arrest during routine procedures. Each new category, such as spinal cord injuries, muscular dystrophy, and severe infections, was added to the warning list only after enough cases accumulated to make the pattern undeniable.

The pediatric muscular dystrophy cases were especially influential in changing practice. The accumulation of reports of apparently healthy children dying after succinylcholine administration led to formal warnings from anesthesiology societies and drug regulators. In the United States, the FDA added a boxed warning to succinylcholine labeling regarding its use in children, and clinical guidelines shifted toward recommending nondepolarizing agents as the default for pediatric anesthesia. The drug’s history is a case study in how an adverse effect that seemed rare at first turned out to be predictable once the underlying mechanism was understood. The risk is not random. It follows directly from the state of the patient’s muscle membrane, and once clinicians know what to look for, most cases are preventable.